Bicycle Therapeutics PLC
NASDAQ:BCYC
Bicycle Therapeutics PLC
Revenue
Bicycle Therapeutics PLC
Revenue Peer Comparison
Competitive Revenue Analysis
Latest Figures & CAGR of Competitors
Company | Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Bicycle Therapeutics PLC
NASDAQ:BCYC
|
Revenue
$41.6m
|
CAGR 3-Years
55%
|
CAGR 5-Years
31%
|
CAGR 10-Years
N/A
|
|
Centessa Pharmaceuticals PLC
NASDAQ:CNTA
|
Revenue
$6.9m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Exscientia PLC
NASDAQ:EXAI
|
Revenue
£20.1m
|
CAGR 3-Years
17%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Autolus Therapeutics PLC
NASDAQ:AUTL
|
Revenue
$1.7m
|
CAGR 3-Years
0%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Immunocore Holdings PLC
NASDAQ:IMCR
|
Revenue
£249.4m
|
CAGR 3-Years
102%
|
CAGR 5-Years
60%
|
CAGR 10-Years
N/A
|
|
Genus PLC
LSE:GNS
|
Revenue
£673.1m
|
CAGR 3-Years
6%
|
CAGR 5-Years
7%
|
CAGR 10-Years
6%
|
See Also
What is Bicycle Therapeutics PLC's Revenue?
Revenue
41.6m
USD
Based on the financial report for Mar 31, 2024, Bicycle Therapeutics PLC's Revenue amounts to 41.6m USD.
What is Bicycle Therapeutics PLC's Revenue growth rate?
Revenue CAGR 5Y
31%
Over the last year, the Revenue growth was 168%. The average annual Revenue growth rates for Bicycle Therapeutics PLC have been 55% over the past three years , 31% over the past five years .